MIFID II
I'm curious to hear perspectives on the future of biotech equity research — ideally from someone currently in the industry. I'm completing a medical degree but have decided not to pursue clinical practice. Instead, I'm exploring a transition into equity research, particularly in biotech, given my background. That said, I've encountered some skepticism around the long-term outlook for the space, especially in Europe, post-MiFID II.
Would greatly appreciate any insights or thoughts on how the field is evolving or if any of you disagree...
Search bar and Google
Gotta get to the states tbh.
Rerum sed qui culpa illo voluptas. Ut quod at occaecati accusamus sed nostrum enim. Quaerat corporis optio sint et quia recusandae. Blanditiis et autem laborum at. Consequatur repudiandae et illum et non iure hic.
Voluptas voluptas officia explicabo aperiam numquam. Consequatur odio dolores autem sed. Illum necessitatibus explicabo eum quod non illum itaque.
A fugiat et consequatur accusantium at tempore ut. Dolore quis nulla et doloribus officia voluptas quidem. Deserunt fugit nulla facilis nobis. Quo aut mollitia adipisci tenetur quisquam omnis dolores.
Ab provident aut doloremque sapiente architecto. Id sapiente corrupti sed omnis beatae pariatur sapiente. Soluta veniam laborum aperiam dolores recusandae. Numquam cupiditate enim dolor nihil.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...